论文部分内容阅读
目的探讨红霉素与阿奇霉素不同给药途径下治疗呼吸道支原体(mycoplasma pneumoniae,MP)感染的临床效果。方法收集2011年1月——2014年1月本院收治的MP感染患儿123例,随机均分为A组、B组和C组,各41例。A组予以阿奇霉素序贯治疗,阿奇霉素10 mg/(kg·d)静脉滴注3~5 d,序贯阿奇霉素颗粒剂10mg/(kg·d)口服4d,B组予以阿奇霉素静滴治疗,阿奇霉素静脉滴注10 mg/(kg·d),5~7 d,C组予以红霉素静滴治疗,红霉素30 mg/(kg·d)静脉滴注,2次/d,7~14 d,计量资料采用t检验,计数资料采用χ2检验,P<0.05为差异有统计学意义。结果 A组的治疗总有效率为97.56%,显著高于B组的82.93%和C组的63.41%,且B组显著高于C组,对比差异均有统计学意义(均P<0.05);A组、B组的退热时间、咳嗽消失时间、肺部啰音消失时间、MP-Ig M转阴时间以及住院时间[(3.38±1.09)、(3.52±1.22)、(5.21±0.88)、(5.51±1.23)、(5.78±1.83)、(5.94±2.19)、(15.11±3.19)、(15.57±3.87)、(5.33±2.78)、(6.15±3.09)d]比较差异均无统计学意义(均P>0.05),但均相比于C组显著缩短[(4.73±1.15)、(10.19±1.18)、(11.79±2.23)、(23.24±2.23)、(11.92±3.42)d],对比差异均有统计学意义(均P<0.05)。A组的不良反应率为7.32%,显著低于B组的26.83%和C组的51.22%,且B组显著低于C组,对比差异均有统计学意义(均P<0.05)。结论阿奇霉素序贯治疗MP感染疗效显著,优于阿奇霉素或者红霉素静脉滴注治疗,不良反应较少,值得在临床中推广应用。
Objective To investigate the clinical effects of different routes of administration of erythromycin and azithromycin in the treatment of mycoplasma pneumoniae (MP) infection. Methods 123 patients with MP infection admitted to our hospital from January 2011 to January 2014 were randomly divided into A group, B group and C group, 41 cases each. A group was given azithromycin sequential treatment, azithromycin 10 mg / (kg · d) intravenous infusion of 3 ~ 5 d, sequential azithromycin granules 10mg / (kg · d) orally for 4 days, B group to azithromycin intravenous infusion, azithromycin vein Erythromycin was intravenously dripped in group C, erythromycin 30 mg / (kg · d) was intravenously dripped twice per day for 7-14 days , Measurement data using t test, count data using χ2 test, P <0.05 for the difference was statistically significant. Results The total effective rate of treatment group A was 97.56%, significantly higher than that of group B 82.93% and group C 63.41%, and group B was significantly higher than that of group C (all P <0.05). The duration of cough disappearance, the time of pulmonary rales disappearance, MP-Ig M negative conversion time and length of hospital stay [(3.38 ± 1.09), (3.52 ± 1.22), (5.21 ± 0.88), (5.51 ± 1.23), (5.78 ± 1.83), (5.94 ± 2.19), (15.11 ± 3.19), (15.57 ± 3.87), (5.33 ± 2.78), (6.15 ± 3.09) d] (All P> 0.05), but both were significantly shorter than those in group C (4.73 ± 1.15, 10.19 ± 1.18, 11.79 ± 2.23, 23.24 ± 2.23, 11.92 ± 3.42, respectively] The differences were statistically significant (all P <0.05). The adverse reaction rate of group A was 7.32%, which was significantly lower than that of group B (26.83%) and group C (51.22%), and group B was significantly lower than group C (all P <0.05). Conclusion Sequential azithromycin treatment of MP infection was significantly better than the azithromycin or erythromycin intravenous infusion, with fewer adverse reactions, it is worth to promote the clinical application.